How I Treat Advanced Head Neck Cancer

Somnath Roy; Joydeep Ghosh; Sandip Ganguly

doi:10.1055/s-0042-1742320

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY 4.0 · Indian J Med Paediatr Oncol 2024; 45(04): 327-334
DOI: 10.1055/s-0042-1742320

How I Treat

How I Treat Advanced Head Neck Cancer

Somnath Roy

¹Department of Medical Oncology, Tata Medical Center, Newtown, Kolkata, West Bengal, India

,

Joydeep Ghosh

¹Department of Medical Oncology, Tata Medical Center, Newtown, Kolkata, West Bengal, India

,

Sandip Ganguly

¹Department of Medical Oncology, Tata Medical Center, Newtown, Kolkata, West Bengal, India

References
1 356-india-fact-sheets.pdf [Internet]. [cited 2020 Sep 6]. Accessed December 7, 2021: https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf
2 Shah SB, Sharma S, D'Cruz AK. Head and neck oncology: the Indian scenario. South Asian J Cancer 2016; 5 (03) 104-105
3 Mohanti BK, Nachiappan P, Pandey RM, Sharma A, Bahadur S, Thakar A. Analysis of 2167 head and neck cancer patients' management, treatment compliance and outcomes from a regional cancer centre, Delhi, India. J Laryngol Otol 2007; 121 (01) 49-56
4 Parikh P, Patil V, Agarwal JP. et al; Indian Cooperative Oncology Network. Guidelines for treatment of recurrent or metastatic head and neck cancer. Indian J Cancer 2014; 51 (02) 89-94
5 Vermorken JB, Mesia R, Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359 (11) 1116-1127
6 Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol 2015; 33 (29) 3293-3304
7 Patil V, Noronha V, Dhumal SB. et al. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. Lancet Glob Health 2020; 8 (09) e1213-e1222
8 Ministry of Statistics and Program Implementation | Government Of India [Internet]. [cited 2020 Oct 13]. Accessed December 7, 2021: http://www.mospi.gov.in/
9 Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group Study. Cancer Treat Rep 1985; 69 (06) 577-581
10 Al-Sarraf M, Metch B, Kish J. et al. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. Cancer Treat Rep 1987; 71 (7-8): 723-726
11 Forastiere AA, Metch B, Schuller DE. et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10 (08) 1245-1251
12 Gibson MK, Li Y, Murphy B. et al; Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23 (15) 3562-3567
13 Schöffski P, Catimel G, Planting AST. et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC early clinical studies group. Ann Oncol 1999; 10 (01) 119-122
14 Baur M, Kienzer H-R, Schweiger J. et al. Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial. Cancer 2002; 94 (11) 2953-2958
15 Urba S, van Herpen CML, Sahoo TP. et al. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. Cancer 2012; 118 (19) 4694-4705
16 Williams SD, Velez-Garcia E, Essessee I, Ratkin G, Birch R, Einhorn LH. Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate. Cancer 1986; 57 (01) 18-23
17 Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival | JNCI: Journal of the National Cancer Institute | Oxford Academic [Internet]. [cited 2020 Sep 13]. Accessed December 7, 2021: https://academic.oup.com/jnci/article/90/11/824/916287
18 Chung CH, Ely K, McGavran L. et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24 (25) 4170-4176
19 Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53 (19) 4637-4642
20 Kang X, Patel D, Ng S, Melchior M, Ludwig D, Hicklin J. High affinity Fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab. J Clin Oncol 2007; 25 (18) 3041-3041
21 Guigay J, Fayette J, Mesia R. et al. TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol 2019; 37 (15) 6002-6002
22 Weber J, McCormack PL. Panitumumab: in metastatic colorectal cancer with wild-type KRAS. BioDrugs 2008; 22 (06) 403-411
23 Vermorken JB, Stöhlmacher-Williams J, Davidenko I. et al; SPECTRUM investigators. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013; 14 (08) 697-710
24 Ancevski Hunter K, Socinski MA, Villaruz LC. PD-L1 testing in guiding patient selection for PD-1/PD-L1 inhibitor therapy in lung cancer. Mol Diagn Ther 2018; 22 (01) 1-10
25 Bauml JM, Aggarwal C, Cohen RB. Immunotherapy for head and neck cancer: where are we now and where are we going?. Ann Transl Med 2019; 7 (3, Suppl 3) S75
26 Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE- 048): a randomised, open-label, phase 3 study. - The Lancet [Internet] [cited 2020 Sep 20]. Accessed December 7, 2021: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32591–7/fulltext
27 Dabkara D, Ganguly S, Biswas B, Ghosh J. Metronomic therapy in metastatic castrate-resistant prostate cancer: experience from a tertiary cancer care center. Indian J Cancer 2018; 55 (01) 94-97
28 De Felice F, Musio D, Tombolini V. Head and neck cancer: metronomic chemotherapy. BMC Cancer 2015; 15: 677 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603691/ Accessed December 7, 2021 [Internet]
29 Ferris RL, Licitra L, Fayette J. et al. Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use. Clin Cancer Res 2019; 25 (17) 5221-5230
30 Cohen EEW, Soulières D, Le Tourneau C. et al; KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019; 393 (10167): 156-167
31 Pêtre A, Dalban C, Karabajakian A. et al. Carboplatin in combination with weekly paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule. Oncotarget 2018; 9 (31) 22038-22046
32 Rapidis A, Sarlis N, Lefebvre J-L, Kies M. Docetaxel in the treatment of squamous cell carcinoma of the head and neck. Ther Clin Risk Manag 2008; 4 (05) 865-886
33 Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; Jun 1; 25 (16) 2171-2177
34 Baselga J, Trigo JM, Bourhis J. et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23 (24) 5568-5577
35 Zandberg DP, Algazi AP, Jimeno A. et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer 2019; 107 (107) 142-152
36 Ferris RL, Haddad R, Even C. et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol 2020; 31 (07) 942-950
37 Stewart JSW, Cohen EEW, Licitra L. et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. [corrected] J Clin Oncol 2009; 27 (11) 1864-1871
38 Guo Y, Ahn M-J, Chan A. et al. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. Ann Oncol 2019; 30 (11) 1831-1839
39 Patil VM, Noronha V, Joshi A. et al. Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer. J Clin Oncol 2019; 37 (32) 3032-3041
40 Michel L, Ley J, Wildes TM. et al. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol 2016; 58: 41-48
41 Adkins D, Ley J, Neupane P. et al. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. Lancet Oncol 2019; 20 (09) 1295-1305
42 Soulières D, Faivre S, Mesía R. et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol 2017; 18 (03) 323-335
43 Keam B, Kim S, Ahn Y-O. et al. In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Res 2015; 35 (01) 175-182
44 Zeng Z, Fan S, Zhang X. et al. Epstein-Barr virus-encoded small RNA 1 (EBER-1) could predict good prognosis in nasopharyngeal carcinoma. Clin Transl Oncol 2016; 18 (02) 206-211
45 Jeon YK, Lee BY, Kim JE, Lee SS, Kim CW. Molecular characterization of Epstein-Barr virus and oncoprotein expression in nasopharyngeal carcinoma in Korea. Head Neck 2004; 26 (07) 573-583
46 Zhang W, Chen Y, Chen L. et al. The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases. Medicine (Baltimore) 2015; 94 (20) e845
47 Lee AW, Ng WT, Chan LL. et al. Evolution of treatment for nasopharyngeal cancer–success and setback in the intensity-modulated radiotherapy era. Radiother Oncol 2014; 110 (03) 377-384
48 Al-Sarraf M, LeBlanc M, Giri PG. et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16 (04) 1310-1317
49 Chan AT, Leung SF, Ngan RK. et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005; 97 (07) 536-539
50 Baujat B, Audry H, Bourhis J. et al; MAC-NPC Collaborative Group. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006; 64 (01) 47-56
51 Ribassin-Majed L, Marguet S, Lee AWM. et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol 2017; 35 (05) 498-505
52 Wang M, Tian H, Li G. et al. Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials. Oncotarget 2016; 7 (30) 48375-48390
53 Zhang Y, Chen L, Hu GQ. et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 2019; 381 (12) 1124-1135
54 Sun Y, Li WF, Chen NY. et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016; 17 (11) 1509-1520
55 Zhang L, Huang Y, Hong S. et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 2016; 388 (10054): 1883-1892
56 Chan AT, Hsu MM, Goh BC. et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005; 23 (15) 3568-3576
57 Hsu C, Lee SH, Ejadi S. et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol 2017; 35 (36) 4050-4056
58 Ma BBY, Lim WT, Goh BC. et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol 2018; 36 (14) 1412-1418